CN113286820B - 用于靶向分拣蛋白受体和抑制血管生成拟态的方法和化合物 - Google Patents

用于靶向分拣蛋白受体和抑制血管生成拟态的方法和化合物 Download PDF

Info

Publication number
CN113286820B
CN113286820B CN201980069301.0A CN201980069301A CN113286820B CN 113286820 B CN113286820 B CN 113286820B CN 201980069301 A CN201980069301 A CN 201980069301A CN 113286820 B CN113286820 B CN 113286820B
Authority
CN
China
Prior art keywords
compound
seq
cancer
sortilin
peptide compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980069301.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN113286820A (zh
Inventor
R·贝利沃
B·阿纳比
M·德梅勒
A·拉罗克
J-C·柯里
A·兹格海布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transfert Plus SC
Original Assignee
Transfert Plus SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus SC filed Critical Transfert Plus SC
Publication of CN113286820A publication Critical patent/CN113286820A/zh
Application granted granted Critical
Publication of CN113286820B publication Critical patent/CN113286820B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980069301.0A 2018-08-24 2019-08-26 用于靶向分拣蛋白受体和抑制血管生成拟态的方法和化合物 Active CN113286820B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862722726P 2018-08-24 2018-08-24
US62/722,726 2018-08-24
US201962804063P 2019-02-11 2019-02-11
US62/804,063 2019-02-11
PCT/CA2019/051170 WO2020037434A1 (en) 2018-08-24 2019-08-26 Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry

Publications (2)

Publication Number Publication Date
CN113286820A CN113286820A (zh) 2021-08-20
CN113286820B true CN113286820B (zh) 2025-04-08

Family

ID=69591094

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980069301.0A Active CN113286820B (zh) 2018-08-24 2019-08-26 用于靶向分拣蛋白受体和抑制血管生成拟态的方法和化合物

Country Status (8)

Country Link
US (1) US20220000971A1 (https=)
EP (1) EP3844190A4 (https=)
JP (1) JP7592320B2 (https=)
CN (1) CN113286820B (https=)
AU (1) AU2019324747A1 (https=)
CA (1) CA3110414A1 (https=)
IL (1) IL281043A (https=)
WO (1) WO2020037434A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
CA3006313C (en) 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
CN116731113A (zh) * 2022-03-01 2023-09-12 上海智肽生物科技有限公司 针对sort1的多肽化合物及其药物偶联物
CN119403786A (zh) 2022-06-23 2025-02-07 德罗普尼尔生物有限公司 选择性诱导细胞外靶标在溶酶体中降解的双功能分子
CN120641133A (zh) * 2022-11-14 2025-09-12 瑟瑞技术公司 用于刺激抗肿瘤免疫应答的药物缀合物化合物
WO2025054707A1 (en) * 2023-09-11 2025-03-20 Theratechnologies Inc. Peptide conjugates of camptothecin analogs and uses thereof
WO2025208212A1 (en) * 2024-04-02 2025-10-09 Theratechnologies Inc. Combination therapies comprising peptide-drug conjugates targeting sortilin
WO2025236098A1 (en) * 2024-05-16 2025-11-20 Theratechnologies Inc. Peptide conjugates of maytansinoids and uses thereof
WO2026021513A1 (zh) * 2024-07-25 2026-01-29 上海湃鸿生物科技有限公司 一种多肽药物偶联物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017088058A1 (en) * 2015-11-24 2017-06-01 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
CN107921047A (zh) * 2015-06-03 2018-04-17 台睿生物科技股份有限公司 芳基喹啉衍生物作为血管生成拟态抑制剂的新用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921047A (zh) * 2015-06-03 2018-04-17 台睿生物科技股份有限公司 芳基喹啉衍生物作为血管生成拟态抑制剂的新用途
WO2017088058A1 (en) * 2015-11-24 2017-06-01 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Also Published As

Publication number Publication date
JP2021535209A (ja) 2021-12-16
JP7592320B2 (ja) 2024-12-02
AU2019324747A1 (en) 2021-04-01
WO2020037434A1 (en) 2020-02-27
CN113286820A (zh) 2021-08-20
EP3844190A4 (en) 2022-06-08
CA3110414A1 (en) 2020-02-27
IL281043A (en) 2021-04-29
EP3844190A1 (en) 2021-07-07
US20220000971A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
CN113286820B (zh) 用于靶向分拣蛋白受体和抑制血管生成拟态的方法和化合物
CA3093327C (en) Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
AU2018238165C1 (en) Antibody binding specifically to MUC1 and use thereof
AU2015210578B2 (en) Ligand-cytotoxic drug conjugate, preparation method therefor, and uses thereof
KR20240082348A (ko) 항체, 이의 항체-약물 접합체 및 이의 용도
CN108473541B (zh) 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物
WO2019170131A1 (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
JP7827624B2 (ja) 抗ｃｅａ抗体－エキサテカン類似体複合体及びその医薬用途
CN113121639B (zh) 澳瑞他汀类似物及其偶联物、其制备方法及其应用
JP2026048884A (ja) がんを有する対象においてがんを処置することに用いるための抗ｍｅｆｌｉｎ抗体、および当該抗体を含む医薬組成物
EP4163301A1 (en) Humanized anti-gpc-1 antibody
KR20240029062A (ko) 항-protac 항체 및 복합체
CN117999101A (zh) 靶向EGFR的Fc抗原结合片段-药物缀合物
WO2025036480A1 (zh) 化合物以及含有该化合物的抗体偶联药物
EP4491632A1 (en) Ror1-targeted binding molecule and use thereof
WO2025140358A1 (en) A pharmaceutical composition of anti-fgfr3 antibody drug conjugate and applications thereof
WO2024141496A1 (en) Vhh anti-protac antibodies and complexes
HK40117209A (zh) 一种靶向ror1的结合分子及其应用
HK40117209B (zh) 一种靶向ror1的结合分子及其应用
KR20260053355A (ko) 화합물 및 이를 포함하는 항체 약물 접합체
HK40123051A (zh) 化合物以及含有该化合物的抗体偶联药物
JP2025532500A (ja) 抗ｈｅｒ２抗体免疫アゴニスト複合体の医薬組成物及びその用途
CN121494985A (zh) 靶向Trop2/EpCAM的双特异性抗体、抗体偶联药物及其制备方法与应用
HK40017733A (en) Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
HK40017733B (en) Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant